Literature DB >> 16705091

Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study.

Corinne Frère1, David-Alexandre Tregouet, Pierre-Emmanuel Morange, Noémie Saut, Dinar Kouassi, Irène Juhan-Vague, Laurence Tiret, Marie-Christine Alessi.   

Abstract

Recent studies revisiting the association between plasma thrombin-activatable fibrinolysis inhibitor (TAFI) Ag levels and polymorphisms of the CPB2 gene (coding for TAFI) suggested that TAFI Ag levels were influenced by 2 major quantitative trait nucleotides (QTNs) in European whites. However, the strong linkage disequilibrium (LD) between CPB2 polymorphisms in European whites did not allow one to distinguish which polymorphisms could be the putative QTNs. To get a better insight into the identification of QTNs, a transethnic haplotype analysis contrasting 2 populations of African and European subjects was performed using 13 CPB2 polymorphisms. Results of the haplotype analyses suggested that 3 QTNs had independent effects and explained about 15% of the TAFI variability, consistently in the 2 populations. The lower LD observed in the African population enabled us to identify the 1583T>A SNP located in 3'UTR as one of these QTNs, whereas the -2599C>G and -2345--2344insG SNPs located in the 5' region might be the 2 other QTNs. A phylogenetic study suggested that these 3 polymorphisms occurred before the period of migration "out of Africa." Although this transethnic comparison contributed to better map the putative CPB2 QTNs, further studies are required to clarify the role of the promoter region.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16705091     DOI: 10.1182/blood-2006-01-008094

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Genome scan of clot lysis time and its association with thrombosis in a protein C-deficient kindred.

Authors:  M E Meltzer; S J Hasstedt; C Y Vossen; P W Callas; Ph G DE Groot; F R Rosendaal; T Lisman; E G Bovill
Journal:  J Thromb Haemost       Date:  2011-07       Impact factor: 5.824

Review 2.  Finding genes and variants for lipid levels after genome-wide association analysis.

Authors:  Cristen J Willer; Karen L Mohlke
Journal:  Curr Opin Lipidol       Date:  2012-04       Impact factor: 4.776

3.  Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men.

Authors:  Mirjam E Meltzer; Carine J M Doggen; Philip G de Groot; Joost C M Meijers; Frits R Rosendaal; Ton Lisman
Journal:  Haematologica       Date:  2009-04-18       Impact factor: 9.941

4.  Common variants in the GDF5-UQCC region are associated with variation in human height.

Authors:  Serena Sanna; Anne U Jackson; Ramaiah Nagaraja; Cristen J Willer; Wei-Min Chen; Lori L Bonnycastle; Haiqing Shen; Nicholas Timpson; Guillaume Lettre; Gianluca Usala; Peter S Chines; Heather M Stringham; Laura J Scott; Mariano Dei; Sandra Lai; Giuseppe Albai; Laura Crisponi; Silvia Naitza; Kimberly F Doheny; Elizabeth W Pugh; Yoav Ben-Shlomo; Shah Ebrahim; Debbie A Lawlor; Richard N Bergman; Richard M Watanabe; Manuela Uda; Jaakko Tuomilehto; Josef Coresh; Joel N Hirschhorn; Alan R Shuldiner; David Schlessinger; Francis S Collins; George Davey Smith; Eric Boerwinkle; Antonio Cao; Michael Boehnke; Gonçalo R Abecasis; Karen L Mohlke
Journal:  Nat Genet       Date:  2008-01-13       Impact factor: 38.330

5.  Genetic variation in thrombin-activatable fibrinolysis inhibitor is associated with the risk of diabetic nephropathy.

Authors:  C-W Xu; X-B Wu; X-L Ma; Y-S Wang; B-C Zhang; J-J Zhao; Z-J Wang; J Chen
Journal:  J Endocrinol Invest       Date:  2012-07       Impact factor: 5.467

6.  Thrombin-activatable fibrinolysis inhibitor Thr325Ile polymorphism and plasma level in breast cancer: A pilot study.

Authors:  Manal S Fawzy; Eman A Mohammed; Amal S Ahmed; Abeer Fakhr-Eldeen
Journal:  Meta Gene       Date:  2015-04-11

7.  Sex-specific effect of CPB2 Ala147Thr but not Thr325Ile variants on the risk of venous thrombosis: A comprehensive meta-analysis.

Authors:  Nora Zwingerman; Alejandra Medina-Rivera; Irfahan Kassam; Michael D Wilson; Pierre-Emmanuel Morange; David-Alexandre Trégouët; France Gagnon
Journal:  PLoS One       Date:  2017-05-26       Impact factor: 3.240

8.  Genome-wide haplotype analysis of cis expression quantitative trait loci in monocytes.

Authors:  Sophie Garnier; Vinh Truong; Jessy Brocheton; Tanja Zeller; Maxime Rovital; Philipp S Wild; Andreas Ziegler; Thomas Munzel; Laurence Tiret; Stefan Blankenberg; Panos Deloukas; Jeannette Erdmann; Christian Hengstenberg; Nilesh J Samani; Heribert Schunkert; Willem H Ouwehand; Alison H Goodall; François Cambien; David-Alexandre Trégouët
Journal:  PLoS Genet       Date:  2013-01-31       Impact factor: 5.917

9.  Association between polymorphisms in the flanking region of the TAFI gene and atherosclerotic cerebral infarction in a Chinese population.

Authors:  You Li; Zhiliang Zeng; Jianghao Zhao; Guoda Ma; Lili Cui; Hua Tao; Zhijun Lin; Yanyan Chen; Bin Zhao; Yusen Chen; Keshen Li
Journal:  Lipids Health Dis       Date:  2014-05-13       Impact factor: 3.876

10.  A Genome-wide Study of Common and Rare Genetic Variants Associated with Circulating Thrombin Activatable Fibrinolysis Inhibitor.

Authors:  Tara M Stanne; Maja Olsson; Erik Lorentzen; Annie Pedersen; Anders Gummesson; Ann Gils; Katarina Jood; Gunnar Engström; Olle Melander; Paul J Declerck; Christina Jern
Journal:  Thromb Haemost       Date:  2018-01-29       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.